职称：助理研究员

        头衔：求是博士后

        电话：0371-65587009

        邮箱：tingxuangu@zzu.edu..cn

        地址：河南省金水区东明路127号河南省肿瘤医院1号楼506

个人简介

2017年获得生物化学与分子生物学硕士学位，2023年获得郑州大学医学博士学位，2023年至今，任郑州大学医学科学院助理研究员。

主要研究方向

主要从事病毒感染与炎症损伤的化学预防方面的研究，目前的研究工作主要集中在两个方面：1. 病毒感染后引起肺部炎症因子风暴的动物模型构建；2.治疗新冠肺炎临床试验新候选药物的早期发现和转化。

荣誉及获奖情况

代表性成果

1. Lu N^*, Gu T^*, Tian X, et al. Acetylshikonin inhibits inflammatory responses and Papain-like protease activity in murine model of COVID-19[J]. Signal Transduction and Targeted Therapy, 2022, 7(1): 371

2.Tian X^*, Gu T^*, Patel S, et al. CRISPR/Cas9–An evolving biological tool kit for cancer biology and oncology[J]. NPJ precision oncology, 2019, 3(1): 1-8.

3.Gu T^*, Zhao S^*, Jin G, et al. Cytokine signature induced by SARS-CoV-2 spike protein in a mouse model[J]. Frontiers in Immunology, 2021, 11: 621441.

4.Tian X^*, Gu T^*, Lee M H, et al. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2022, 1877(1): 188645.

5.Wang Y^*, Gu T^*, Tian X, et al. A small molecule antagonist of PD-1/PD-L1 interactions acts as an immune checkpoint inhibitor for NSCLC and melanoma immunotherapy[J]. Frontiers in Immunology, 2021: 1372.

6.Ge Z^*, Gu T^*, Zhang L, et al. The phosphatase of regenerating liver-3 protein (PRL-3) promotes glioma cell invasiveness by interacting with β3–tubulin[J]. Bioengineered, 2022, 13(2): 4112-4121.  

7.Gu T^*, Tian X^*, Wang Y, et al. Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint[J]. Frontiers in Immunology, 2023, 14: 2031.

相关专利

1.喷他脒在制备抑制 PD1 和 PD-L1 蛋白之间相互作用药物中的应用, 201910285204.7

2.聚肌胞苷酸和SARS-CoV-2棘突蛋白在构建小鼠ARDS模型中的应用，202010499454.3

3.APPLICATION OF POLYINOSINIC ACID AND SARS-COV-2 SPIKE PROTEIN IN CONSTRUCTION OF MOUSE ARDS MODEL， PCT/CN2021/093023